Structure-Based Repurposing of FDA-Approved Drugs as TNF-α Inhibitors

被引：39

作者：

Leung, Chung-Hang ^{[1
]}

Chan, Daniel Shiu-Hin ^{[2
]}

Kwan, Maria Hiu-Tung ^{[2
]}

Cheng, Zhen ^{[2
]}

Wong, Chun-Yuen ^{[3
]}

Zhu, Guo-Yuan ^{[1
]}

Fong, Wang-Fun ^{[1
]}

Ma, Dik-Lung ^{[2
]}

机构：

[1] Hong Kong Baptist Univ, Sch Chinese Med, Ctr Canc & Inflammat Res, Kowloon Tong, Hong Kong, Peoples R China

[2] Hong Kong Baptist Univ, Dept Chem, Kowloon Tong, Hong Kong, Peoples R China

[3] City Univ Hong Kong, Dept Biol & Chem, Kowloon, Hong Kong, Peoples R China

来源：

CHEMMEDCHEM | 2011年 / 6卷 / 05期

关键词：

drug discovery; approved drugs; inhibitors; tumor necrosis factor; virtual screening; JANUARY-1; FEBRUARY; 2005; LOWER URINARY-TRACT; ABANDONED DRUGS; DISCOVERY; EZETIMIBE; IDENTIFICATION; COMMERCIALIZE; PHILADELPHIA; THERAPIES; IDENTIFY;

D O I：

10.1002/cmdc.201100016

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Old dogs, new tricks! We applied structure-based virtual screening methods to identify small-molecule inhibitors of tumor necrosis factor-α (TNF-α) from a database of 3000 US Food and Drug Administration (FDA)-approved drugs. Darifenacin (Enablex) and ezetimibe (Zetia) were identified as direct TNF-α inhibition, representing only the fifth and sixth examples of small-molecule TNF-α inhibitors. © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

引用

页码：765 / 768

页数：4

共 29 条

[1] The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society (Reprinted from Neurourology and Urodynamics, vol 21, pg 167-178, 2002) [J].

Abrams, P ;

Cardozo, L ;

Fall, M ;

Griffiths, D ;

Rosier, P ;

Ulmsten, U ;

Van Kerrebroeck, P ;

Victor, A ;

Wein, A .

UROLOGY, 2003, 61 (01) :37-49

[2] Muscarinic receptor antagonists for overactive bladder [J].

Abrams, Paul ;

Andersson, Karl-Erik .

BJU INTERNATIONAL, 2007, 100 (05) :987-1006

[3] Signalling pathways of the TNF superfamily: A double-edged sword [J].

Aggarwal, BB .

NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756

[4] Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence [J].

Andersson, KE ;

Wein, AJ .

PHARMACOLOGICAL REVIEWS, 2004, 56 (04) :581-631

[5] Integration of virtual and high-throughput screening [J].

Bajorath, F .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) :882-894

[6] A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia [J].

Bays, HE ;

Ose, L ;

Fraser, N ;

Tribble, DL ;

Quinto, K ;

Reyes, R ;

Johnson-Levonas, AO ;

Sapre, A ;

Donahue, SR .

CLINICAL THERAPEUTICS, 2004, 26 (11) :1758-1773

[7] Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs [J].

Bisson, W. H. ;

Cheltsov, A. V. ;

Bruey-Sedano, N. ;

Lin, B. ;

Chen, J. ;

Goldberger, N. ;

May, L. T. ;

Christopoulos, A. ;

Dalton, J. T. ;

Sexton, P. M. ;

Zhang, X.-K. ;

Abagyan, R. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (29) :11927-11932

[8]

Carley DW, 2005, IDRUGS, V8, P310

[9]

Carley DW, 2005, IDRUGS, V8, P306

[10]

Chan D.S.-H., 2010, ANGEW CHEM, V122, P2922, DOI DOI 10.1002/ANGE.200907360

← 1 2 3 →